3-methyl-N-(((1R,6S)-2,2,6-trimethylcyclohexyl)methyl)aniline hydrochloride | 1441168-00-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methyl-N-(((1R,6S)-2,2,6-trimethylcyclohexyl)methyl)aniline hydrochloride
• 英文别名: 3-methyl-N-[[(1R,6S)-2,2,6-trimethylcyclohexyl]methyl]aniline;hydrochloride
• CAS: 1441168-00-8
• 化学式: C₁₇H₂₇N*ClH
• 分子量: 281.869
• InChiKey: VWJIKCWYRHNFOJ-KUARMEPBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.29
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  trans-2,2,6-trimethylcyclohexanecarboxaldehyde 在 盐酸 、 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 3.0h， 生成 3-methyl-N-(((1R,6S)-2,2,6-trimethylcyclohexyl)methyl)aniline hydrochloride
  参考文献：
  名称：

  [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE
  [FR] LIGANDS LIANT L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  揭示了用于治疗由于或与在眼睛中积聚的有毒视觉循环产物有关的眼科疾病的化合物和组合物，例如干性成人黄斑变性，以及由于或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂的组合物，以及使用这些化合物和/或组合物的治疗方法。还揭示了合成这些药剂的方法。

  公开号：

  WO2013081642A1

文献信息

• Opsin-Binding Ligands, Compositions and Methods of Use
  申请人：Bikam Pharmaceuticals, Inc.

  公开号：US20150038574A1

  公开（公告）日：2015-02-05

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  本文披露了一些化合物和组合物，用于治疗由于或与眼睛中毒性视觉循环产物积累有关的眼科疾病，如干性成人黄斑变性，以及由突变视蛋白的错误折叠和/或视蛋白的错误定位引起或有关的疾病。描述了这些化合物单独或与其他治疗剂组合的组合物，以及使用这些化合物和/或组合物的治疗方法。还披露了合成这些药剂的方法。
• Opsin-binding ligands, compositions and methods of use
  申请人：Bikam Pharmaceuticals, Inc.

  公开号：US10040749B2

  公开（公告）日：2018-08-07

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  所公开的化合物和组合物可用于治疗因产生积聚在眼内的有毒视觉循环产物而引起或与之相关的眼科疾病，如干性成人黄斑变性，以及因突变视蛋白的错误折叠和/或视蛋白的错误定位而引起或与之相关的疾病。此外，还描述了这些化合物单独或与其他治疗剂结合的组合物，以及使用这些化合物和/或组合物的治疗方法。还公开了合成此类制剂的方法。
• Bispecific chimeric antigen receptors and methods of use thereof to treat cancer
  申请人：Seattle Children's Hospital

  公开号：US10189903B2

  公开（公告）日：2019-01-29

  The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

  本发明涉及一种双特异性嵌合抗原受体，它包括(a)至少两个抗原特异性靶向区；(b)胞外间隔结构域；(c)跨膜结构域；(d)至少一个共刺激结构域；以及(e)胞内信号转导结构域，其中每个抗原特异性靶向区包括抗原特异性单链Fv（scFv）片段，并结合不同的抗原，且双特异性嵌合抗原受体与治疗对照共同表达。本发明还提供了双特异性嵌合抗原受体的方法和用途。
• Polynucleotides encoding bispecific chimeric antigen receptors
  申请人：Seattle Children's Hospital

  公开号：US10829556B2

  公开（公告）日：2020-11-10

  The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

  本发明涉及一种双特异性嵌合抗原受体，它包括(a)至少两个抗原特异性靶向区；(b)胞外间隔结构域；(c)跨膜结构域；(d)至少一个共刺激结构域；以及(e)胞内信号转导结构域，其中每个抗原特异性靶向区包括抗原特异性单链Fv（scFv）片段，并结合不同的抗原，且双特异性嵌合抗原受体与治疗对照共同表达。本发明还提供了双特异性嵌合抗原受体的方法和用途。
• OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE
  申请人：Bikam Pharmaceuticals, Inc.

  公开号：EP2785178B1

  公开（公告）日：2019-05-01